Revolutionizing Rheumatoid Arthritis Treatment: Psychedelics Biotech Co. Touts New Patent

Psychedelics-focused biopharmaceutical company Silo Pharma, Inc. (NASDAQ: SILO) announced on Wednesday that the U.S. Patent and Trademark Office has issued Patent 16/825,371 titled "Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis, and Imaging of Diseases and Disorders."

The new patent covers the company's portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. SPU-21 has been shown to inhibit arthritic progression in a preclinical animal model.

Eric Weisblum, the company's CEO, touted the many benefits of the company's new patent. 

"Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis," Weisblum said in a press release. "The expanded claims in this new patent grant reinforce protection for our ongoing development of SPU-21 guided delivery of targeted psilocybin as a therapeutic agent for rheumatoid arthritis (RA), our initial indication."

SILO Price Action

Silo Pharma's shares traded 0.24% higher at $2.095 per share at the time of writing on Wednesday morning.

Related News

• Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making
• Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help?
• Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds

Photo: Courtesy of owfiqu barbhuiya on Unsplash